Satsuma Pharmaceuticals, Inc. (“Satsuma”) located in California, USA, was established in 2016 licensing in nasal delivery technology originally developed by Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”). Satsuma was listed on the NASDAQ Stock Market on September 13, 2019. 

Satsuma is developing a nasal migraine drug, STS101 (dihydroergotamine). In the Phase I clinical study, STS101 achieved high absorption that was rapid and consistent using SNBL’s nasal delivery platform. Satsuma initiated a Phase III EMERGE™ clinical study with 1,140 migraine patients and is anticipating generation of top-line data within the second half of 2020.

SNBL’s license agreement with Satsuma for use of proprietary nasal delivery technology is limited to the development of STS101. If STS101 proceeds according to Satsuma’s development timeline, the new-drug application (NDA) will be submitted to the FDA in 2021 and the drug will subsequently be available to patients. Royalties will be paid to SNBL based on sales.

See the attached PDF for details.